PMA P100034 – NovoTTF-100A System (Optune): approval order and indications for use (2011)

Government Record · U.S. Food and Drug Administration, Center for Devices and Radiological Health · April 8, 2011

U.S. Food et al., 2011-04-08: Original PMA approval of the NovoTTF-100A System (later Optune) on 8 April 2011 for recurrent glioblastoma after chemotherapy, as monotherapy.

THE DEVICE IS INDICATED FOR TREATMENT OF ADULT PATIENTS (22 YEARS OF AGE OR OLDER) WITH HISTOLOGICALLY- CONFIRMED GLIOBLASTOMA MULTIFORME

PMA database page, Approval Order Statement (matches approval letter p.1, 8 April 2011)

U.S. Food et al., 2011-04-08: Original PMA approval of the NovoTTF-100A System (later Optune) on 8 April 2011 for recurrent glioblastoma after chemotherapy, as monotherapy. Date received 08/16/2010; decision 04/08/2011; product code NZK; advisory committee Neurology; trial NCT00379470; expedited review granted. The approval-order PDF is a scanned OCR copy with a poor text layer ('Pubjic I etih Service'), so the excerpt is taken from the PMA database page's clean Approval Order Statement; the two agree. The page's hyphen spacing ('HISTOLOGICALLY- CONFIRMED') is the source's rendering. Study type: regulatory record.